Silence Therapeutics (SLN) Cash & Equivalents (2018 - 2026)

Silence Therapeutics has disclosed Cash & Equivalents across 9 years of filings, most recently posting $5.7 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $5.7 million, down 91.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.7 million (down 91.28% YoY), and the FY2025 annual result was $11.3 million, down 90.71% from the prior year.
• Cash & Equivalents came in at $5.7 million for Q1 2026 at Silence Therapeutics, down from $11.3 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $121.3 million in Q4 2024 to a low of $5.7 million in Q1 2026.
• The 5-year median for Cash & Equivalents is $45.5 million (2022), against an average of $50.9 million.
• Across the five-year window, Cash & Equivalents surged 291.13% in 2024 and slumped 91.28% in 2026, its largest moves.
• Silence Therapeutics' Cash & Equivalents stood at $49.2 million in 2022, then slumped by 37.01% to $31.0 million in 2023, then soared by 291.13% to $121.3 million in 2024, then tumbled by 90.71% to $11.3 million in 2025, then plunged by 49.84% to $5.7 million in 2026.
• The last three Cash & Equivalents figures came in at $5.7 million (Q1 2026), $11.3 million (Q4 2025), and $82.0 million (Q3 2025), per Business Quant data.